Previous close | 45.62 |
Open | 45.05 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 43.75 - 45.05 |
52-week range | 26.00 - 49.62 |
Volume | |
Avg. volume | 332,666 |
Market cap | N/A |
Beta (5Y monthly) | 0.90 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.
Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: